和铂医药创始人、董事长兼首席执行官王劲松博士表示："和铂医药在新型治疗性抗体的发现与开发领 域已建立起卓越声誉。本次合作不仅体现公司在该领域的专业积淀，其模式更是超越了传统的授权交 易。公司与经验丰富的投资机构携手，以股东身份共同创立了一家全球性生物技术公司，专注于推进公 司的核心抗体产品HBM4003。这一创新合作模式不仅有助于创造长期价值，也使和铂医药能够持续深 度参与并推动该产品的全球开发进程。" 根据协议，和铂医药将获得总价值逾 1.05 亿美元的前期对价，包括现金形式的 5000 万美元首付款、 500 万美元近期付款以及价值逾 5000 万美元的 Solstice Oncology 股权。此外，基于未来特定里程碑事 件的达成，和铂医药还有资格进一步获得最高约 11 亿美元的开发、监管及商业里程碑付款，以及基于 大中华区以外地区净销售额的分级特许权使用费。 和铂医药与Solstice Oncology(一家由多个头部风险投资机构联合创立的临床阶段生物技术公司)达成授 权协议及股权合作，授予对方一款临床阶段候选产品HBM4003在大中华区以外地区的独家开发及商业 化权益。 ...

Core Viewpoint - The company has entered into an exclusive licensing and equity cooperation agreement with Solstice Oncology to develop and commercialize its clinical-stage asset HBM4003 outside Greater China, which is expected to enhance its global collaboration network and maximize the scientific and commercial value of its technology platform [1][2]. Financial Terms - The agreement includes upfront payments exceeding $105 million, comprising a $50 million upfront fee, a $5 million recent payment, and over $50 million in equity issued by Solstice Oncology [1]. - The company is also eligible for up to approximately $1.1 billion in additional milestone payments based on development, regulatory, and commercial achievements, as well as tiered royalties based on net sales of HBM4003 outside Greater China [1]. Strategic Implications - This collaboration is aimed at accelerating the global development and commercialization of HBM4003 outside Greater China by leveraging the expertise of experienced investment institutions [2]. - The partnership is expected to create long-term value and allow the company to deeply engage in and drive the global development process of the asset [2].

Core Viewpoint - The company has entered into an exclusive licensing and equity cooperation agreement with Solstice Oncology to develop and commercialize its clinical-stage asset HBM4003 outside Greater China, which is expected to enhance its global collaboration network and maximize the scientific and commercial value of its technology platform [1][2] Group 1 - The agreement includes upfront payments exceeding $105 million, comprising a $50 million upfront payment, a $5 million recent payment, and over $50 million in equity issued by Solstice Oncology [1] - The company is also eligible for up to approximately $1.1 billion in additional milestone payments based on development, regulatory, and commercial achievements, as well as tiered royalties based on net sales of HBM4003 outside Greater China [1] - This collaboration aims to accelerate the global development and commercialization of HBM4003, allowing the company to deeply engage in and drive the global development process of the asset [2]

Core Viewpoint - The company has entered into an exclusive licensing and equity cooperation agreement with Solstice Oncology for the development and commercialization of its clinical-stage asset HBM4003 outside Greater China, which is expected to enhance its global collaboration network and maximize the scientific and commercial value of its technology platform [1][2] Group 1: Agreement Details - The agreement allows the company to grant exclusive rights to Solstice Oncology for the development and commercialization of HBM4003 outside Greater China [1] - The company is eligible to receive over $105 million in upfront payments, including a $50 million initial payment, a $5 million recent payment, and over $50 million in equity issued by Solstice Oncology [1] - The company may also receive up to approximately $1.1 billion in additional milestone payments based on development, regulatory, and commercial achievements, as well as tiered royalties based on net sales of HBM4003 outside Greater China [1] Group 2: Strategic Implications - The company aims to leverage this opportunity to strengthen its global collaboration network through innovative cooperation models [2] - The agreement facilitates the establishment of a global biotechnology company focused on the development of HBM4003 in partnership with experienced investment institutions, accelerating its global development and commercialization [2] - This cooperation model is expected to create long-term value and enable the company to deeply engage in and drive the global development process of the asset [2]

Core Viewpoint - The European Union (EU) has announced that starting in 2026, Chinese researchers will be excluded from the "Horizon Europe" cooperation program, marking a shift from partnership to strategic competition in the tech sector between China and the EU [1][3]. Group 1: Horizon Europe Program - "Horizon Europe" is the EU's flagship research and innovation program, dating back to the 1980s, which has attracted applicants from over 100 countries [1]. - In the previous funding cycle (2014-2020), the program had a budget of approximately 800 billion euros, with the US and China being the top non-EU participants [1]. - The program prioritizes fields such as artificial intelligence and quantum technology [1]. Group 2: New Regulations and Restrictions - The new regulations, introduced in December, specifically outline restrictions against Chinese institutions, citing "research security and potential military applications" as the rationale [3]. - The ban will cover critical areas including artificial intelligence, quantum technology, semiconductors, and biotechnology, requiring non-Chinese researchers to prove that their partners are not affiliated with Chinese institutions [3]. - However, Chinese institutions will still be able to apply for or participate in specific research projects related to climate, biodiversity, food, and agriculture [4]. Group 3: Reactions and Implications - Experts have expressed that the ban may not significantly harm China but could lead to greater isolation for Europe [6][7]. - Concerns have been raised regarding the EU's focus on intellectual property issues, with some arguing that the real risk of IP theft lies more with commercial entities than with researchers making cutting-edge discoveries [6]. - The shift in policy reflects a broader trend of geopolitical factors shaping research relationships, with warnings that such restrictions could reduce the EU's ability to attract Chinese talent and fragment the global research landscape [7].

Group 1 - The stock price of Jiajie Ankang-B (02617.HK) has shown a downward trend recently, with a closing price of HKD 67.80 on February 16, reflecting a daily decline of 1.38% [1] - On February 20, the closing price further decreased to HKD 66.60, marking a daily drop of 1.77% [1] - From February 16 to February 20, the stock experienced a cumulative decline of 3.13% and a volatility of 7.13%, with relatively low trading volume and turnover rate [1] Group 2 - On February 20, the total net inflow was HKD 4.9268 million, but the net inflow from major funds was zero, indicating active participation from retail investors [1] - During the same period, the biotechnology sector increased by 1.64%, but the individual stock performance diverged from the sector trend [1]

Product Development Progress - The company has completed the recruitment of 104 patients for the Phase III clinical trial of its core product IMM01 (Tidutamab) for first-line treatment of chronic myelomonocytic leukemia (CMML) as of December 31, 2025, with plans to complete the recruitment of 132 patients by the end of March 2026 for mid-term analysis [1] - If the mid-term analysis data meets expectations, the company plans to submit a pre-BLA (pre-Biologics License Application) to regulatory authorities by the end of 2026, which is a critical step towards commercialization [1] - On January 12, 2026, IMM01 received approval from the National Medical Products Administration of China to initiate clinical trials for the treatment of atherosclerosis, with plans to advance this area to Phase Ib/II studies by 2026 [1] Business Progress - The Phase III registration clinical trial for another core product, IMM0306 (CD47xCD20 bispecific antibody), targeting relapsed refractory follicular lymphoma, is set to begin patient recruitment by the end of January 2026 [1] - The company has terminated its licensing agreement with Instil Bio's subsidiary Axion Bio, reclaiming global rights to IMM2510 (PD-L1xVEGF bispecific antibody) and IMM27M (CTLA-4 antibody), while retaining a payment of $35 million [2] - The founder stated that the company is in discussions with multiple multinational pharmaceutical companies to seek new partners for global development in 2026 [2] Company Status - On February 10, 2026, the company provided a loan of 13.7247 million RMB to its founder, indicating a good financial condition that will not affect daily operations [3] Industry Policy Status - The company is focused on tumor immunotherapy and was established in 2015, listing on the Hong Kong Stock Exchange in 2023, with a research pipeline that includes 14 candidate drugs centered around the CD47 target [4]

Core Insights - McKinsey's report identifies 18 industry sectors likely to reshape the global business landscape, predicting revenues of $29 trillion to $48 trillion by 2040, contributing 18-34% to global GDP growth [2] E-commerce - By 2040, e-commerce's share of global retail revenue is expected to rise to 27%-38%, up from approximately 20% currently [3] - Growth drivers include market expansion in developing countries and new product categories in developed nations, such as healthcare and emotionally valuable products [4] - Significant investments are anticipated in customer acquisition and last-mile delivery across e-commerce platforms [5] Electric Vehicles - Electric vehicles (EVs) are projected to exceed 50% of global passenger car sales by 2040 [6] - Breakthroughs in battery technology and smart algorithms will significantly influence this sector, prompting increased R&D investments from both EV manufacturers and traditional automakers [7] Cloud Services - The demand for higher storage and computing capabilities is driven by a more interconnected world and the need for AI products requiring substantial computational power [9] - The cloud services industry experienced a 17% compound annual growth rate (CAGR) from 2005 to 2020, with similar growth expected in the coming decades [10] Semiconductors - The semiconductor industry is essential for the digital world, with demand from computing, data storage, automotive, communication, and industrial electronics driving growth [11] - A sustained CAGR of 6%-8% is forecasted for the semiconductor sector over the next decade [11] AI Software Services - The rapid development of AI has led to its classification as a distinct sector, with increasing usage of AI assistants [12] - Companies in the AI space are engaged in a competitive race to develop advanced foundational models and applications [13] Digital Advertising - Digital advertising, through search, social media, and media services, is expanding in value as internet usage among the middle class increases [14] - Continuous algorithm improvements enhance platforms' abilities to target customers and track advertising costs, although competition for user attention necessitates increased investment in engaging content [15] Streaming Video - Investment in customer acquisition and content production is rising, prompting streaming platforms to seek new revenue models [17] - Developing countries may provide incremental growth in subscription and advertising revenue for streaming services, with projections indicating over 1 billion households subscribing to long-form video services by 2040 [18] Shared Autonomous Vehicles - The advent of autonomous driving technology may reduce the necessity for personal vehicle ownership [19] - By 2040, shared autonomous vehicles could account for 25%-51% of shared mobility revenue [20] Space Economy - The world is on the brink of entering a space economy era, with advancements in reusable rocket technology transforming the aerospace industry [21][22] Cybersecurity - Cybercrime caused approximately $950 billion in direct economic losses in 2020, with indirect losses potentially reaching $4-6 trillion [24] - Increasing awareness of cybersecurity has led companies to enhance their investments in this area [25] Batteries - Significant advancements in battery technology have tripled energy density over the past few decades [26] - The global energy transition is driving demand for batteries, particularly in electric vehicles, energy storage, and consumer electronics, with EVs expected to represent over 80% of the battery market by 2040 [28] Video Games - By 2030, an estimated 40% of the global population may become video game players [30] - New gaming models, such as mobile and cloud gaming, are accelerating market growth, with free-to-play games generating substantial revenue [32] Robotics - The integration of AI with robotics is creating significant expectations for humanoid robots, which are seen as potential "ultimate intelligent agents" [33] Industrial and Consumer Biotechnology - Breakthroughs in gene editing and other technologies are accelerating the application of biotechnology in agriculture, alternative proteins, consumer products, and bio-materials [37] Modular Construction - Modular construction methods, which involve prefabricating building components for on-site assembly, can significantly enhance construction efficiency [38] Nuclear Fission Power - The development of safer, smaller modular reactors presents opportunities to supplement renewable energy sources [39] Air Traffic - Electric vertical takeoff and landing vehicles and delivery drones are expected to drive significant technological changes in air traffic [41] Obesity Treatment Drugs - The prevalence of obesity is projected to rise from 15% in 2020 to 24% by 2035, indicating a potential market for effective weight loss products [43]

Stock Performance - On February 16, 2026, the closing price of Baiaosaitu-B (02315.HK) was HKD 50.95, reflecting a daily decline of 4.77% with a trading volume of 18,000 shares and a turnover of approximately HKD 924,500, indicating a low turnover rate of only 0.02% [1] - The stock price fell below the 5-day moving average of HKD 52.03, while the upper Bollinger Band at HKD 54.957 exerted pressure on the stock price, suggesting a weakening short-term upward momentum [1] - In contrast, the Hang Seng Index rose by 0.52%, while the biotechnology sector, to which the company belongs, experienced a slight decline of 0.02%, indicating a divergence between the stock's performance and the sector's trend [1] Capital Movements - Vico (Hong Kong) Trading Co., Ltd. increased its holdings by 786,000 H-shares at an average price of HKD 27.2784 per share on February 2, raising its ownership from 7.31% to 8.02%, with this change disclosed on February 16 [2] - The purchase price was significantly lower than the closing price of HKD 50.95 on February 16, which may raise concerns among investors regarding short-term valuation pressure [2]

Summary of Allogene Therapeutics Conference Call Company Overview - **Company**: Allogene Therapeutics (NasdaqGS:ALLO) - **Event**: 2026 Conference at Citi's Virtual Oncology Leadership Summit - **Key Speaker**: Zach Roberts, Chief Medical Officer Core Industry and Product Insights - **Product**: Cema-cel, an off-the-shelf allogeneic CAR T cell therapy targeting CD19 - **Study**: ALPHA-3 study, focusing on newly diagnosed large B-cell lymphoma patients - **Study Design**: Patients achieving remission after standard frontline treatment undergo a minimal residual disease (MRD) test. MRD positive patients are randomized to either observation or treatment with cema-cel [3][4][5][6] Key Points and Arguments - **Efficacy and Safety**: Cema-cel has shown comparable efficacy to autologous CAR T products with improved safety profiles, including lower rates of cytokine release syndrome (CRS) and immune effector cell-associated neurotoxicity syndrome (ICANS) [4][5] - **MRD Testing**: The ALPHA-3 study utilizes a highly sensitive PCR-based MRD test to identify patients at high risk of relapse. The study aims to determine if treating MRD positive patients with cema-cel can improve long-term outcomes [6][8] - **Expected Outcomes**: A 25%-30% absolute improvement in MRD clearance is anticipated between the treatment and observation arms. Historical data suggests a baseline MRD clearance rate of around 20% in the observation arm [11][12][14] - **Clinical Context**: The study is positioned as a frontline treatment, with MRD status being a new eligibility criterion for treatment decisions. This approach is innovative compared to traditional methods that do not incorporate MRD testing [15][16] Additional Important Insights - **Patient Journey**: The study allows for flexibility in treatment decisions based on individual patient circumstances, with a significant proportion of patients being treated in community settings [36][37] - **Enrollment Progress**: Initial challenges in patient enrollment have been addressed, and the study is now seeing routine MRD testing for eligible patients [40][41] - **Commercial Strategy**: Allogene anticipates a significant market opportunity for cema-cel, especially as MRD testing becomes more prevalent. The acquisition of Foresight Diagnostics by Natera is expected to enhance MRD testing capabilities [35][58] - **Future Expectations**: The upcoming futility analysis in April is viewed as a critical milestone that could de-risk the overall study and potentially revolutionize treatment practices for lymphoma patients [70][72] Conclusion - Allogene Therapeutics is poised to make significant advancements in the treatment of large B-cell lymphoma through the ALPHA-3 study and the use of cema-cel. The integration of MRD testing into treatment protocols represents a paradigm shift in patient management and could lead to improved outcomes for patients at risk of relapse [72]